AZD 5718

Drug Profile

AZD 5718

Alternative Names: AZD5718

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary artery disease
  • Phase I Cardiovascular disorders

Most Recent Events

  • 31 Oct 2017 Phase-II clinical trials in Coronary artery disease in Denmark, Sweden (PO) (NCT03317002)
  • 26 Oct 2017 AstraZeneca plans a phase II trial for Coronary artery disease in Denmark, Finland and Sweden (PO) in October 2017 (NCT03317002)
  • 26 Aug 2017 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Coronary artery disease presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top